Alexion Pharmaceuticals Inc., of New Haven, Conn., said data published in JCI Insight from an open-label phase II trial involving children, ages 6 to 12.5 at study entry, with hypophosphatasia showed that those treated for up to five years with Strensiq sustained improvements seen at the six-month primary endpoint cutoff, including improvements in patient growth, strength, motor function, agility and quality of life, which for most patients meant achieving normal values for age- and sex-matched peers.